Schering In Talks With Potential Partners For HDL Cholesterol Therapy

Schering and Merck’s cholesterol franchise continues to gain growth in terms of market share, but sequential sales of the combination therapy Vytorin fall flat.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet